-
| Exchange | NASDAQ |
|---|---|
| ISIN | US4327051011 |
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | USD |
| Dividend Yield | 0.0% |
|---|---|
| Beta | nan |
| Target Price | 4 |
| Market Cap | 4M |
| PE Ratio | None |
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HILS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025